David A. Siegel Essa Pharma Inc. Transaction History

Two Sigma Advisers, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.65 - $3.31 $67,310 - $84,074	-25,400 Reduced 30.86%	56,900 $175,000
Q2 2023 Aug 14, 2023	SELL	$2.6 - $3.34 $367,900 - $472,610	-141,500 Reduced 63.23%	82,300 $222,000
Q1 2023 May 15, 2023	BUY	$2.56 - $3.55 $132,352 - $183,535	51,700 Added 30.04%	223,800 $664,000
Q4 2022 Feb 14, 2023	SELL	$1.5 - $4.82 $255,450 - $820,846	-170,300 Reduced 49.74%	172,100 $433,000
Q3 2022 Nov 14, 2022	BUY	$1.75 - $3.44 $509,775 - $1 Million	291,300 Added 570.06%	342,400 $623,000
Q2 2022 Aug 15, 2022	SELL	$3.15 - $7.94 $194,985 - $491,486	-61,900 Reduced 54.78%	51,100 $161,000
Q1 2022 May 16, 2022	SELL	$6.18 - $14.44 $268,830 - $628,140	-43,500 Reduced 27.8%	113,000 $698,000
Q4 2021 Feb 14, 2022	SELL	$7.8 - $14.38 $3.18 Million - $5.87 Million	-408,300 Reduced 72.29%	156,500 $2.22 Million
Q3 2021 Nov 15, 2021	BUY	$7.76 - $29.37 $4.07 Million - $15.4 Million	525,000 Added 1319.1%	564,800 $4.52 Million
Q2 2021 Aug 16, 2021	BUY	$24.17 - $34.28 $476,149 - $675,316	19,700 Added 98.01%	39,800 $1.14 Million
Q1 2021 May 17, 2021	BUY	$11.61 - $32.08 $233,361 - $644,808	20,100 New	20,100 $584,000

35.1M

15.8K

21K

Ticker EPIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,073,100
Market Cap $72.3M
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreem...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.